A clinical formulation indicated for Autoimmune Care. This product supports the regulation of immune system responses to prevent organ rejection following tissue transplantation.
An immunosuppressive antimetabolite developed to manage organ rejection and intended to alleviate overactive immune responses to support transplant success and target autoimmune conditions.
Mechanism of Action
It inhibits the enzyme IMPDH, which is essential for the synthesis of guanosine nucleotides. Since T and B-cells depend on this for proliferation, it effectively suppresses the immune response.
Route of Administration
Oral
Onset Time
Variable
Duration
12 hours
Contraindications
Pregnancy, Breastfeeding, Allergy to mycophenolate
Severe Adverse Events
Severe bone marrow suppression, Sepsis, Increased risk of lymphoma, Birth defects, GI bleeding
Common Side Effects
Nausea, Diarrhea, Stomach upset
Uncommon Side Effects
Headache, Vomiting, High blood pressure, Anemia, Infection risk
Drug Interactions
Antacids, Cholestyramine, Acyclovir, Valaciclovir, Azathioprine, Live vaccines
Pregnancy Safety Warnings
Contraindicated; causes high risk of miscarriage and severe birth defects.
Information for CellCept is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
